Consistent with this is the recent finding that activation of the PD1-pathway by treatment with programmed death-ligand 1 (PD-L1) fusion proteins may be protective in a model of lethal experimental cerebral malaria (CM) due to inhibition of CD8+ T cells derived cytotoxicity (46). Here, CD8A is linked to cutaneous mastocytosis.